Summary
Other Scenarios:
- PDLI - GB
- GB - SMA
| Buyer: | PDL Biopharma Inc (PDLI) | Last Price: | 6.18 | Market Cap.: | 863.93M |
|---|---|---|---|---|---|
| Target: | Symmetry Medical Inc (SMA) | Last Price: | 8.32 | Market Cap.: | 302.21M |
Lines of Business Summary:
- PDL Biopharma Inc (PDLI) competes in 1 industry and 26 product/service groups
- Symmetry Medical Inc (SMA) competes in 2 industries and 34 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- PDL Biopharma Inc (PDLI) has 2 and Symmetry Medical Inc (SMA) has 2 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Healthcare |
|
|
732 |
Biopharmaceuticals |
|
334 | |
|
Healthcare Services |
|
122 | |
|
Medical Devices |
|
177 | |
|
Outsourced Biomedical Services |
|
|
39 |
|
Industrial and Materials |
|
889 | |
|
Industrial Manufacturing |
|
390 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 10)
|
Target (Total: 91)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 1)
|
Target (Total: 0)n/a |
Buyer (Total: 8)
|
Target (Total: 11)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 8 | 2,797 |
| Revenue Per Employee | 61,231,260.0 | 135,833.0 |
| Total Revenue | 77.3 | 100.7 |
| Total Expenses | 6.9 | n/a |
Other Revenue
|
n/a | n/a |
|
Cost of Revenue
|
n/a | 75.5 |
|
SG&A Expense
|
n/a | 18.7 |
|
Research & Development
|
n/a | n/a |
|
Other Operating Expense
|
n/a | n/a |
|
Operating Income
|
70.4 | 100.7 |
|
Unusual Income
|
n/a | 0.4 |
|
LT Debt to Capital
|
n/a | n/a |
|
Fwd P/E
|
4.32 | 14.51 |
|
Fwd P/Rev
|
2.29 | 0.71 |
| Book Value | -243.8 | 306.0 |
|
Curr Portion of LTD/Cap Lease
|
69.5 | 8.8 |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Outsourced Biomedical Services > Drug Discovery Services > Lead Discovery/Validation/Optimization > Lead Biologics > Antibodies
Target
Focused ():
Healthcare > Outsourced Biomedical Services > Development/Manufacturing Services > Contract Manufacturing Organizations (CMO) > Medical Device OEM
Business Description
Buyer
PDL BioPharma, Inc. (PDL) is engaged in the management of its antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with pharmaceutical and biotechnology companies. The Company receives royalties based on these license agreements on sales of a number of humanized antibody products marketed and also may receive royalty payments on additional humanized antibody products launched before final patent expiry in December 2014. The Company has entered into licensing agreements with numerous entities that are independently developing or have developed humanized antibodies pursuant to which it has licensed certain rights under its Queen et al. patents to make, use, sell, offer for sale and import humanized antibodies. It receives royalties on net sales of products that are made, used or sold prior to patent expiry. In general, these agreements cover antibodies targeting antigens specified in the license agreements.
Target
Symmetry Medical Inc. (Symmetry) is an independent provider of implants and related instruments and cases to global orthopedic device manufacturers. It designs, develops and produces the products for companies in other segments of the medical device market, including the dental, osteobiologic and endoscopy segments. The Company also provides limited specialized products to non-healthcare markets, such as the aerospace market. The Company?s products include implants, including forged, cast and machined products for the global orthopedic device market; instruments used in the placement and removal of orthopedic implants and in other surgical procedures; cases, including plastic, metal and hybrid cases used to organize, secure and transport medical devices for orthopedic, endoscopy, dental and other surgical procedures, and other specialized products for the aerospace market. In August 2011, the Company acquired Olsen Medical.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
100 | 21.15 |
|
Operating Margin %
|
97.61 | 29.07 |
|
Quick Ratio
|
1.26 | 1.31 |
|
Current Ratio
|
1.38 | 2.84 |
|
Coverage Ratio
|
n/a | n/a |
| Total Assets | 235.0 | 642.3 |
| Return on Equity % | n/a | 3.08 |
| Return on Assets % | 197.31 | 1.47 |
|
Cash+ ST Inv. Per Share
|
1.12 | 0.64 |
| Total Debt | 398.6 | 262.8 |
| Total Debt to Equity % | 0 | 85.87 |
| Total Debt to Tangible Equity % | n/a | n/a |
|
Debt to Asset %
|
169.66 | 40.92 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
|
|
|
|
Healthcare Services |
|
|
|
Healthcare Distributors
The Distributors Subsector is comprised of companies that distribute a wide variety of healthcare products, equipment and supplies to healthcare service providers and institutions.
|
|
|
|
Medical Devices |
|
|
|
Cardiology
The Cardiology Subsector includes medical devices that diagnose, monitor, and treat diseases affecting the heart and proximal blood vessels. Common devices include vital sign monitors, cardiac defibrillators, pacemakers, and other surgical equipment.
|
|
|
|
General Surgery
The General Surgery Subsector includes medical devices that perform general, non-specialty surgeries; these devices are often general in scope and are used in procedures involving various parts of the body.
|
|
|
|
Medical Supplies
The Medical Supplies Subsector includes basic and consumable products that are widely used in healthcare settings.
|
|
|
|
Neurology
The Neurology Subsector includes medical devices that diagnose, monitor and treat neurological disorders.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes medical devices that diagnose and treat female reproductive diseases; devices used to care for women during pregnancy, childbirth, and the post-partum period are also included in this sector.
|
|
|
|
Orthopedics
The Orthopedics Subsector includes medical devices that diagnose and treat musculoskeletal diseases involving muscles, bones and joints.
|
|
|
|
Urology
The Urology Subsector includes medical that diagnose and treat urinary tract and male reproductive disorders.
|
|
|
|
Vascular
The Vascular Subsector includes medical devices that diagnose and treat of conditions affecting the blood vessels.
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Drug Discovery Services
The Drug Discovery Services Subsector includes companies that provide biopharmaceutical companies with novel biological targets and drug leads.
|
|
|
|
Industrial and Materials |
|
|
|
Industrial Manufacturing |
|
|
|
Aerospace and Defense
Aerospace and Defense is comprised of products and services with applications in aviation, space exploration, combat and national security, small arms, and other defense and security purposes.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
Upper Respiratory |
|
|
|
Monoclonal Antibodies
Therapeutics that treat allergic reactions by specifically binding and inhibiting inflammatory substances.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Intestinal Disorders |
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Crohn`s Disease |
|
|
|
Alpha 4 Integrin Inhibitors
Therapeutics that prevent/inhibit the inflammation process by blocking the action of integrin, molecules involved in the inflammation process.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
|
Hemoglobinuria |
|
|
|
Monoclonal Antibodies
Therapeutics that treat hemoglobinuria by specifically binding to the C5 complement component and inhibiting its activation.
Buyer Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Immunotherapy |
|
|
|
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Crohn`s Disease |
|
|
|
Alpha 4 Integrin Inhibitors
Therapeutics that prevent/inhibit the inflammation process by blocking the action of integrin, molecules involved in the inflammation process.
Buyer Products:
|
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Alpha 4 Integrin Inhibitors
Therapeutics that prevent/inhibit the inflammation process by blocking the action of integrin, molecules involved in the inflammation process.
Buyer Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Atypical Hemolytic Uremic Syndrome (aHUS) |
|
|
|
Monoclonal Antibodies
Therapeutics that treat Atypical Hemolytic Uremic Syndrome by specifically binding certain receptors implicated with the disease.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Skeletal Disorders |
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Immunotherapy |
|
|
|
Monoclonal Antibodies
Therapeutics that treat ankylosing spondylitis interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Immunotherapy |
|
|
|
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neuromuscular Disorders |
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Alpha 4 Integrin Inhibitors
Therapeutics that prevent/inhibit the inflammation process by blocking the action of integrin, molecules involved in the inflammation process.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Localized |
|
|
|
Monoclonal Antibodies
Therapeutics that treat breast cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of breast cancer cells and inhibit the cancer cells' growth and induce their death.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Colon Cancer/Colorectal Cancer |
|
|
|
Metastatic |
|
|
|
Monoclonal Antibodies
Therapeutics that treat colorectal cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
|
|
|
|
Gastric Cancer (Stomach Cancer) |
|
|
|
Metastatic |
|
|
|
Monoclonal Antibodies
Therapeutics that treat gastric cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Brain Cancer |
|
|
|
Glioma |
|
|
|
Glioblastoma |
|
|
|
Monoclonal Antibodies
Therapeutics that treat and manage tumors of the glial cells by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Buyer Products:
|
|
|
|
Respiratory System/Thoracic |
|
|
|
Lung Cancer |
|
|
|
Non Small Cell Lung Cancer (NSCLC) |
|
|
|
Monoclonal Antibodies
Therapeutics that treat lung cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
|
Metastatic |
|
|
|
Monoclonal Antibodies
Therapeutics that treat kidney cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Degenerative Disorders |
|
|
|
Edema |
|
|
|
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular edema by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.
Buyer Products:
|
|
|
|
Macular Degeneration (AMD) |
|
|
|
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular degeneration by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Prophylactic Treatments |
|
|
|
Monoclonal Antibodies
Therapeutics that treat asthma with monoclonal antibodies.
Buyer Products:
|
|
|
|
Transplantation |
|
|
|
Renal (Kidney) |
|
|
|
Rejection Prophylaxis |
|
|
|
Monoclonal Antibodies
Protein-based therapeutics that target specific substances like proteins.
Buyer Products:
|
|
|
|
Healthcare Services |
|
|
|
Healthcare Distributors |
|
|
|
Medical Equipment Distributors |
|
|
|
General
Distribution of equipment and supplies used in a wide variety of medical settings.
Target Products:
|
|
|
|
Medical Devices |
|
|
|
Cardiology |
|
|
|
Surgical |
|
|
|
General Procedure |
|
|
|
Instruments |
|
|
|
Manual Instruments
Devices used to perform general cardiac surgery that do not require electrical power, including retractors, forceps, clamps, scissors, knives and other similar surgical items.
Target Products:
|
|
|
|
General Surgery |
|
|
|
Invasive |
|
|
|
Instruments |
|
|
|
Electrical |
|
|
|
Electrosurgical |
|
|
|
Attachments/Handpieces |
|
|
|
Bipolar
Electrosurgical equipment that utilize bipolar technology in which the electric current flows between the two tips of the instrument, including cutting/coagulating probes, forceps and clamps.
Target Products:
|
|
|
|
Monopolar
Electrosurgical equipment which utilize the monopolar technology, in which the electric current flows between the instrument's electrode to the dispersive grounding pad, including scissors, bisectors, forceps, clamps and cutting probes. Monopolar electrosurgical instruments are used to grasp and retain tissue during electrosurgical procedures.
Target Products:
|
|
|
|
Generators |
|
|
|
Bipolar
Electrical generators designed to produce current for bipolar electrosurgical equipment
Target Products:
|
|
|
|
Manual Instruments
Medical devices used manually by surgeons to perform invasive general surgical procedures, such as scalpels, curettes, dissectors, elevators, forceps, osteotomes, retractors, bisectors and other similar items.
Target Products:
|
|
|
|
Medical Supplies |
|
|
|
Safety and Sterilization |
|
|
|
Sterilization |
|
|
|
Tools/Supplies Protection
Devices used to prepare, store and handle surgical devices, which include covers, wraps, tray liners, pouches, cassettes and others.
Target Products:
|
|
|
|
Treatment |
|
|
|
Wound Management |
|
|
|
Cleaning/Healing Devices
Devices used to clean and facilitate healing of wounds, such as bandages, dressings, cleansers, anti-infective ointments, sponges, cold compresses and other similar items.
Target Products:
|
|
|
|
Neurology |
|
|
|
Surgical |
|
|
|
General Procedure |
|
|
|
Cerebrospinal Fluid (CSF) Management |
|
|
|
External Drainage |
|
|
|
Catheters
A long slender wire-like tube device that allows spinal fluid to drain through it out of the body.
Target Products:
|
|
|
|
Drainage Systems
Systems designed to facilitate spinal fluid drainage, often including catheters, valves and monitors.
Target Products:
|
|
|
|
Intracranial Pressure (ICP) Systems
Sensors that are planted within brain cavities such as the meninges in order to monitor brain fluid pressure.
Target Products:
|
|
|
|
Implanted Drainage |
|
|
|
Valves
A device that provides the ability to open or close a tube through which spinal fluid flows.
Target Products:
|
|
|
|
Instruments |
|
|
|
Electrical |
|
|
|
Electrosurgical |
|
|
|
Bipolar Attachments
An electrosurgical system that has two electrodes in the tip of the instrument to allow for electrical current to flow out one electrode and then back into the other at the site of contact.
Target Products:
|
|
|
|
Monopolar Attachments
An electrosurgical instrument that uses electrical current as the cutting or coagulation force by way of one electrode passing electricity into the body and it leaving via a grounding pad.
Target Products:
|
|
|
|
Neuroendoscopes
A device that allows for the visual inspection of any cranial cavity by means of an long fiber optic viewing instrument with a light on the end.
Target Products:
|
|
|
|
Manual Instruments
Devices that are used in neurological surgery that do not require electrical power, such as drills, curettes, dissectors, forceps, hooks, retractors, bisectors and other similar items.
Target Products:
|
|
|
|
Procedure Specific |
|
|
|
Cerebral Aneurysm Clips
A little clamp-like device used to treat extrusions or bulges in brain arteries or veins.
Target Products:
|
|
|
|
Cerebral Embolization |
|
|
|
Embolization Material
Various agents such as gelfoam, silastic, metal, or fat that is used to plug up a bleeding brain artery or vein.
Target Products:
|
|
|
|
Guidewires
Guidewires for use specifically in the neurovascular area, generally in the treatment of cerebral emboli.
Target Products:
|
|
|
|
MicroCatheters
Catheters specifically designed to reach small vessels within the brain in order to facilitate delivery of medication or therapeutic devices to diseased or damaged brain tissue.
Target Products:
|
|
|
|
Region Specific |
|
|
|
Brain |
|
|
|
Dural Grafts
Grafts designed to replace and/or repair damaged or diseased dural tissue.
Target Products:
|
|
|
|
Cranium |
|
|
|
Craniotomy |
|
|
|
Instruments |
|
|
|
Electrical |
|
|
|
Craniotomy Kits
Instruments and implements designed for the opening of the skull in order to facilitate brain surgery.
Target Products:
|
|
|
|
Handpieces
Various instruments that attach to a driver or power source and allow the surgeon to perform certain surgical procedures like boring holes or cutting into the skull.
Target Products:
|
|
|
|
Fixation |
|
|
|
Cranioplasty
Devices that hold together pieces of the skull for healing or plug up a surgical hole in the skull for healing purposes.
Target Products:
|
|
|
|
Sets
Complete sets of instruments used to patch up holes or surgical incisions made in the skull.
Target Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Surgical |
|
|
|
General Procedure |
|
|
|
Endoscopic |
|
|
|
Colposcopic |
|
|
|
Instruments |
|
|
|
Manual Instruments
Instruments used to perform surgery on the cervix that do not require electrical power,
such as forceps, curettes, hooks, speculums, ligature carriers, retractors and other similar items.
Target Products:
|
|
|
|
Orthopedics |
|
|
|
Surgical |
|
|
|
General Procedure |
|
|
|
Invasive |
|
|
|
Instruments |
|
|
|
Manual Instruments
Mechanical instruments used in musculoskeletal surgical procedures, such as blades, curettes, broaches, shavers, elevators, tensioners, osteotomes, retractors, rongeurs and other similar items.
Target Products:
|
|
|
|
Procedure Specific |
|
|
|
Fixation |
|
|
|
Bone |
|
|
|
Internal |
|
|
|
Metallic |
|
|
|
Specific |
|
|
|
Spine
Internal metallic fixation devices used to immobilize spine fractures.
Target Products:
|
|
|
|
Urology |
|
|
|
Surgical |
|
|
|
General Procedure |
|
|
|
Invasive |
|
|
|
Instruments |
|
|
|
Retractors
Surgical instruments used retract or move organs or tissue to access specific organs.
Target Products:
|
|
|
|
Vascular |
|
|
|
Surgical |
|
|
|
Procedure/Region Specific |
|
|
|
Percutaneous Transluminal Angioplasty (PTA) |
|
|
|
Catheters |
|
|
|
Balloon
Catheters equipped with an expanding balloon at the tip
Target Products:
|
|
|
|
Restenosis Prevention |
|
|
|
Stents Systems |
|
|
|
Peripheral
Stents designed to be placed in peripheral blood vessels.
Target Products:
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Development/Manufacturing Services |
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
Medical Device OEM
Contract Manufacturing Organizations that manufacture (and/or design, develop) medical devices and products for other organizations.
Target Products:
|
|
|
|
Drug Discovery Services |
|
|
|
Lead Discovery/Validation/Optimization |
|
|
|
Lead Biologics |
|
|
|
Antibodies
Biological lead compounds which have a specific amino acid sequence that only interacts with specific substances to cause an immunological response.
Buyer Products:
|
|
|
|
Industrial and Materials |
|
|
|
Industrial Manufacturing |
|
|
|
Aerospace and Defense |
|
|
|
Aerospace |
|
|
|
Aviation Equipment |
|
|
|
Aircraft Engine and Engine Parts
Aircraft Engine and Engine Parts is comprised of completed aircraft engines as well as key engine components.
Target Products:
|
|
|
|
Other Aircraft Parts and Auxiliary Equipment and Services
Parts, auxiliary equipment, and specialized services required to build and maintain an aircraft. Some airport equipment is also included.
Target Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
Soligenix Inc
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Greatbatch Inc
|
|
n/a | 485.040 | 18.80 | 11.98 | 0.84 | 0.76 | 37.30 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Roche Holding AG
|
|
n/a | 139,114.120 | 24.15 | 10.09 | 2.04 | 2.93 | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Roche Holding AG
|
|
86.00% | 139,114.120 | 24.15 | 10.09 | 2.04 | 2.93 | n/a | |
|
Elan Corporation PLC
|
|
10.00% | 7,657.835 | 16.83 | -325.00 | 6.27 | 6.23 | 15.28 | |
|
Pfizer Inc
|
|
n/a | 176,093.984 | 12.76 | 10.21 | 1.76 | 2.93 | n/a | |
|
Novartis SA
|
|
n/a | 142,003.622 | 16.43 | 9.70 | 2.40 | 2.46 | 101.58 | |
|
Bristol Myers Squibb Co
|
|
n/a | 55,809.424 | 14.67 | 16.79 | 2.60 | 3.12 | 11.82 | |
|
Biogen IDEC Inc
|
|
n/a | 31,914.176 | 25.95 | 21.64 | 6.21 | 6.01 | 9.58 | |
|
Alexion Pharmaceuticals Inc
|
|
n/a | 15,548.506 | 79.48 | 54.07 | 18.04 | 14.25 | 57.17 | |
|
EKR Therapeutics, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Johnson & Johnson
|
|
31.60% | 173,601.426 | 9.96 | 12.41 | 1.53 | 2.61 | n/a | |
|
Stryker Corp
|
|
11.20% | 19,517.375 | 14.73 | 12.40 | 2.35 | 2.27 | 4.66 | |
|
Medtronic Inc
|
|
n/a | 39,212.786 | 11.59 | 10.13 | 2.39 | 2.37 | 8.64 | |
|
Cardinal Health Inc
|
|
n/a | 14,360.023 | 13.91 | 12.97 | 0.13 | 0.14 | 7.68 | |
|
St Jude Medical Inc
|
|
n/a | 12,511.240 | 15.18 | 11.00 | 2.22 | 2.20 | 20.48 | |
|
Zimmer Holdings Inc
|
|
n/a | 11,211.317 | 15.25 | 11.29 | 2.50 | 2.50 | 5.05 | |
|
Edwards Lifesciences Corp
|
|
n/a | 9,413.673 | 39.81 | 31.05 | 5.43 | 4.85 | 9.65 | |
|
Smith & Nephew PLC
|
|
n/a | 8,156.233 | 4.49 | 11.14 | 1.91 | 1.91 | 4.89 | |
|
OrthoPediatrics Corp
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Biomet, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Karl Storz GmbH & Co. KG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Pfizer Inc
|
|
n/a | 176,093.984 | 12.76 | 10.21 | 1.76 | 2.93 | n/a | |
|
Novartis SA
|
|
n/a | 142,003.622 | 16.43 | 9.70 | 2.40 | 2.46 | 101.58 | |
|
Roche Holding AG
|
|
n/a | 139,114.120 | 24.15 | 10.09 | 2.04 | 2.93 | n/a | |
|
Bristol Myers Squibb Co
|
|
n/a | 55,809.424 | 14.67 | 16.79 | 2.60 | 3.12 | 11.82 | |
|
Biogen IDEC Inc
|
|
n/a | 31,914.176 | 25.95 | 21.64 | 6.21 | 6.01 | 9.58 | |
|
Alexion Pharmaceuticals Inc
|
|
n/a | 15,548.506 | 79.48 | 54.07 | 18.04 | 14.25 | 57.17 | |
|
Elan Corporation PLC
|
|
n/a | 7,657.835 | 16.83 | -325.00 | 6.27 | 6.23 | 15.28 | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 645.3 | 251.5 | 896.8 |
|
Other Revenue
|
n/a | 11.8 | 11.8 |
| Total Revenue | 645.3 | 364.0 | 1,009.2 |
|
Cost of Revenue
|
n/a | 287.0 | 287.0 |
|
SG&A Expense
|
7.7 | 61.8 | 69.5 |
|
Depreciation & Amortization
|
0.0 | n/a | 0.0 |
|
Interest Expense
|
n/a | n/a | n/a |
|
Other Operating Expense
|
n/a | n/a | n/a |
|
Unusual Expense (Income)
|
0.8 | 4.0 | 4.8 |
| Total Expenses | 15.4 | 258.1 | 273.6 |
|
Operating Income
|
629.8 | 105.8 | 735.6 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
-9.0 | -0.9 | -9.9 |
|
Other, Net
|
n/a | 0.2 | 0.2 |
| Income Before Taxes | 548.1 | 3.3 | 551.4 |
| Income Taxes | 192.6 | 0.9 | 193.5 |
| Income After Taxes | 115.9 | 2.4 | 118.3 |
|
Net Income - Excl. Xord. Items
|
115.9 | 2.4 | 118.3 |
|
Net Income - Incl. Xord. Items
|
115.9 | 2.4 | 118.3 |
|
Misc. Earnings Adjustment
|
n/a | -0.0 | -0.0 |
|
Income Avail. to Common
|
115.9 | 2.3 | 118.2 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
139.7 | 35.9 | 175.6 |
|
Basic EPS - Excl. Xord. Items
|
0.83 | 0.04 | 0.67 |
|
Basic EPS - Incl. Xord. Items
|
1.12 | 0.04 | 0.67 |
| Full Dilution Adjustment | 0.8 | 0.0 | 0.9 |
| Fully Diluted Shares Outstanding | 167.0 | 36.2 | 203.3 |
|
F.D. EPS - Excl. Xord. Items
|
0.66 | 0.04 | 0.58 |
|
F.D. EPS - Incl. Xord. Items
|
0.95 | 0.04 | 0.58 |
| Dividends Per Common Share | 0.75 | n/a | 0.75 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
141.4 | 23.2 | 164.5 |
|
ST Investments
|
46.0 | n/a | 46.0 |
|
Accounts Receivable
|
0.6 | 58.3 | 58.9 |
|
Inventory
|
n/a | 81.9 | 81.9 |
|
Prepayments and Advances
|
8.1 | n/a | 8.1 |
|
Other Current Assets
|
10.7 | 13.6 | 24.3 |
|
Current Assets
|
206.2 | 176.9 | 383.1 |
|
PPE
|
n/a | 220.7 | 220.7 |
|
Accum D&A
|
n/a | -115.5 | -115.5 |
|
PPE, Net
|
0.0 | 104.4 | 104.5 |
| Goodwill & Intangibles | n/a | 351.9 | 351.9 |
| Long Term Investments | 5.1 | n/a | 5.1 |
| Other Assets | n/a | n/a | n/a |
|
Other LT Assets
|
16.2 | 9.0 | 25.1 |
| Total Assets | 235.0 | 642.3 | 877.2 |
| Liabilities | |||
| Accounts Payable | 0.5 | 28.2 | 28.7 |
| Payable/Accrued | n/a | n/a | n/a |
| Accrued Expenses | 39.1 | 18.6 | 57.7 |
|
ST Debt
|
n/a | 6.7 | 6.7 |
|
Curr Port of LTD & Cap Lease Oblg
|
69.5 | 8.8 | 78.4 |
| Other (Current) Liabilities | 24.7 | 0.0 | 24.8 |
|
Current Liab.
|
149.6 | 62.3 | 211.9 |
|
LT Debt
|
329.1 | 245.5 | 574.6 |
| Capitalized Lease Obligations | n/a | 1.8 | 1.8 |
|
Total LT Debt
|
340.7 | 261.2 | 602.0 |
| Deferred Taxes | n/a | 19.2 | 19.2 |
|
Other LT Liab.
|
n/a | 7.5 | 7.5 |
|
Total Liabilities
|
473.7 | 337.5 | 811.2 |
| Shareholders Equity | |||
| Common Stock | 1.4 | 0.0 | 1.4 |
| Additional Paid in Capital | -234.8 | 283.9 | 49.1 |
| Retained Earnings | -1.9 | 18.0 | 16.1 |
| Other Equity | -8.5 | 4.2 | -4.4 |
|
Total Equity
|
-243.8 | 306.0 | 62.3 |
|
Total Liab. & Equity
|
230.0 | 643.5 | 873.5 |
|
Shares Outstanding
|
139.7 | 36.4 | 176.1 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 195.0 | 2.4 | 197.4 |
| CF Depreciation | 1.4 | 18.2 | 19.6 |
| CF Amortization | n/a | 4.2 | 4.2 |
| CF Deferred Taxes | 33.2 | -1.6 | 31.6 |
| Other Non-Cash Items | 9.1 | 5.0 | 14.1 |
| Change in Working Capital | -41.6 | 3.8 | -37.8 |
| Total Cash From Operating Activities | 200.8 | 32.0 | 232.8 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | 0.0 | -13.9 | -13.9 |
| Other Investing Cash Flows | 14.4 | -176.5 | -162.1 |
| Total Cash From Investing Activities | 7.0 | -190.4 | -183.5 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -83.8 | n/a | -83.8 |
| Purchase Or Sale of Stock | n/a | -0.4 | -0.4 |
| Purchase and Retirement of Debt | 126.5 | 171.2 | 297.7 |
| Other Financing Cash Flow | -90.6 | -5.6 | -96.2 |
| Total Cash From Financing Activities | -193.1 | 164.1 | -29.0 |
| Exchange Rate Effects | n/a | -0.1 | -0.1 |
| Net Change in Cash | 14.7 | 5.5 | 20.2 |
| Cash Taxes Paid | 0.0 | -1.5 | -1.5 |
| Cash Interest Paid | 0.0 | 5.0 | 5.0 |